Sanofi SA
SNYHealthcare|Drug Manufacturers - General|France
$43.50
-0.40 (-0.91%)
DCF (FCF)
$57.37
Tangible Book
$1.80
Graham Number
$12.04
Earnings Power
$35.15
Upcoming Data Readouts (38)
Jul 2026
Est. completion
Chronic Rhinosinusitis With Nasal Polyposis
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
NCT06393946n=150
Aug 2026
Est. completion
P2Coeliac Disease
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772n=229
Sep 2026
Est. completion
P2Lymphoma
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
NCT05346809n=39
Nov 2026
Est. completion
Type 1 Diabetes
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
NCT07457580n=60
Nov 2026
Est. completion
P2Plasma Cell Myeloma
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT05669989n=70
Dec 2026
Est. completion
P3Pneumococcal Infections
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000n=1,268
Dec 2026
Est. completion
Dec 2026
Est. completion
Pertussis (Whooping Cough)
Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy
NCT06258057n=365,000
Jan 2027
Est. completion
P2Plasma Cell Myeloma Refractory
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571n=64
Jan 2027
Est. completion
P1P2Human Metapneumovirus Immunization
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654n=1,530
Mar 2027
Est. completion
Apr 2027
Est. completion
P4Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
NCT05983068n=48
May 2027
Est. completion
P1P2Meningococcal Immunization
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
NCT06647407n=750
May 2027
Est. completion
P3Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128n=140
Jul 2027
Est. completion
P1P2Relapse Multiple Myeloma
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT07479979n=62
Jul 2027
Est. completion
Sep 2027
Est. completion
P2Hidradenitis Suppurativa
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569n=144
Oct 2027
Est. completion
P2Non-cystic Fibrosis Bronchiectasis
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
NCT07547436n=70
Nov 2027
Est. completion
Chronic Spontaneous Urticaria
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
NCT07316114n=400
Dec 2027
Est. completion
P2Multiple Myeloma
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
NCT04558931n=62
Awaiting Results (5)
Trials past primary completion date but still active — data readout may be imminent.
Dec 2025
P2
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05704049Nov 2025
P4
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06101095May 2022
P2
Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia
NCT05011123